FDA orphan drug designation granted for Autolus’ acute lymphoblastic leukemia drug
There will be an estimated 5,930 new cases of ALL and an estimated 1,500 related deaths in 2019.
Read More
Tag: lymphoblastic lukemia
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
